5,348
Views
18
CrossRef citations to date
0
Altmetric
Perspective

Evolution of a comprehensive, orthogonal approach to sequence variant analysis for biotherapeutics

ORCID Icon, , , , ORCID Icon, ORCID Icon, , , , , , , , & show all
Pages 1-12 | Received 22 Dec 2017, Accepted 29 Sep 2018, Published online: 25 Oct 2018

References

  • Reichert JM. Marketed therapeutic antibodies compendium. mAbs. 2012;4:413–415. doi:10.4161/mabs.19931.
  • Kaplon H, Reichert JM. Antibodies to watch in 2018. mAbs. 2018;10:183–203. doi:10.1080/19420862.2018.1415671.
  • Cafuir LA, Kempton CL. Current and emerging factor VIII replacement products for hemophilia A. Ther Adv Hematol. 2017;8:303–313. doi:10.1177/2040620717721458.
  • Lalonde ME, Durocher Y. Therapeutic glycoprotein production in mammalian cells. J Biotechnol. 2017;251:128–140. doi:10.1016/j.jbiotec.2017.04.028.
  • Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol. 2004;22:1393–1398. doi:10.1038/nbt1026.
  • Borisov OV, Field M, Ling VT, Harris RJ. Characterization of oligosaccharides in recombinant tissue plasminogen activator produced in Chinese hamster ovary cells: two decades of analytical technology development. Anal Chem. 2009;81:9744–9754. doi:10.1021/ac901498k.
  • Mann M, Kelleher NL. Precision proteomics: the case for high resolution and high mass accuracy. Proc Natl Acad Sci U S A. 2008;105:18132–18138. doi:10.1073/pnas.0800788105.
  • Sidoli S, Kulej K, Garcia BA. Why proteomics is not the new genomics and the future of mass spectrometry in cell biology. J Cell Biol. 2017;216:21–24. doi:10.1083/jcb.201612010.
  • Borisov OV, Alvarez M, Carroll JA, Brown PW. Sequence Variants and Sequence Variant Analysis in Biotherapeutic Proteins. In: Schiel JE, Davis DL, Borisov OV, editors. State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 2 Biopharmaceutical Characterization: the NISTmAb Case Study: American Chemical Society; ACS Symposium Series. Washington (DC): American Chemical Society; 2015. p. 63–117.
  • Yang Y, Strahan A, Li C, Shen A, Liu H, Ouyang J, Katta V, Francissen K, Zhang B. Detecting low level sequence variants in recombinant monoclonal antibodies. mAbs. 2010;2:285–298.
  • Frye C, Deshpande R, Estes S, Francissen K, Joly J, Lubiniecki A, Munro T, Russell R, Wang T, Anderson K. Industry view on the relative importance of “clonality” of biopharmaceutical-producing cell lines. Biologicals: J Int Assoc Biol Standardization. 2016;44:117–122. doi:10.1016/j.biologicals.2016.01.001.
  • Calos MP, Lebkowski JS, Botchan MR. High mutation frequency in DNA transfected into mammalian cells. Proc Natl Acad Sci U S A. 1983;80:3015–3019.
  • Razzaque A, Mizusawa H, Seidman MM. Rearrangement and mutagenesis of a shuttle vector plasmid after passage in mammalian cells. Proc Natl Acad Sci U S A. 1983;80:3010–3014.
  • Dorai H, Sauerwald T, Campbell A, Kyung YS, Goldstein J, Magill A, Lewis MJ, Tang QM, Jan D, Ganguly S, et al. Investigation of product microheterogeneity – A case study in rapid detection of mutation in mammalian production cell lines. BioProcess Intl. 2007;66–72.
  • Guo D, Gao A, Michels DA, Feeney L, Eng M, Chan B, Laird MW, Zhang B, Yu XC, Joly J, et al. Mechanisms of unintended amino acid sequence changes in recombinant monoclonal antibodies expressed in Chinese Hamster Ovary (CHO) cells. Biotechnol Bioeng. 2010;107:163–171. doi:10.1002/bit.22780.
  • Zeck A, Regula JT, Larraillet V, Mautz B, Popp O, Gopfert U, Wiegeshoff F, Vollertsen UEE, Gorr IH, Koll H, et al. Low level sequence variant analysis of recombinant proteins: an optimized approach. PloS ONE. 2012;7:e40328. doi:10.1371/journal.pone.0040328.
  • Fu J, Bongers J, Tao L, Huang D, Ludwig R, Huang Y, Qian Y, Basch J, Goldstein J, Krishnan R, et al. Characterization and identification of alanine to serine sequence variants in an IgG4 monoclonal antibody produced in mammalian cell lines. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;908:1–8. doi:10.1016/j.jchromb.2012.09.023.
  • Lin TJ, Beal KM, DeGruttola HS, Brennan S, Marzilli LA, Anderson K. Utilization of sequence variants as biomarkers to analyze population dynamics in cloned cell lines. Biotechnol Bioeng. 2017;114:1744–1752. doi:10.1002/bit.26298.
  • Wong HE, Huang CJ, Zhang Z. Amino acid misincorporation in recombinant proteins. Biotechnol Adv. 2018;36:168–181. doi:10.1016/j.biotechadv.2017.10.006.
  • Zhang Z, Shah B, Bondarenko PV. G/U and certain wobble position mismatches as possible main causes of amino acid misincorporations. Biochemistry. 2013;52:8165–8176. doi:10.1021/bi401002c.
  • Khetan A, Huang YM, Dolnikova J, Pederson NE, Wen D, Yusuf-Makagiansar H, Chen P, Ryll T. Control of misincorporation of serine for asparagine during antibody production using CHO cells. Biotechnol Bioeng. 2010;107:116–123. doi:10.1002/bit.22771.
  • Feeney L, Carvalhal V, Yu XC, Chan B, Michels DA, Wang YJ, Shen A, Ressl J, Dusel B, Laird MW. Eliminating tyrosine sequence variants in CHO cell lines producing recombinant monoclonal antibodies. Biotechnol Bioeng. 2013;110:1087–1097. doi:10.1002/bit.24759.
  • Bostrom J, Haber L, Koenig P, Kelley RF, Fuh G. High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity. PloS ONE. 2011;6:e17887. doi:10.1371/journal.pone.0017887.
  • Harris RJ, Murnane AA, Utter SL, Wagner KL, Cox ET, Polastri GD, Helder JC, Sliwkowski MB. Assessing genetic heterogeneity in production cell lines: detection by peptide mapping of a low level Tyr to Gln sequence variant in a recombinant antibody.Nat Biotechnol. 1993;11:1293–1297.
  • Gu S, Wen D, Weinreb PH, Sun Y, Zhang L, Foley SF, Kshirsagar R, Evans D, Mi S, Meier W, et al. Characterization of trisulfide modification in antibodies. Anal Biochem. 2010;400:89–98. doi:10.1016/j.ab.2010.01.019.
  • Rogers RS, Abernathy M, Richardson DD, Rouse JC, Sperry JB, Swann P, Wypych J, Yu C, Zang L, Deshpande R. A view on the importance of “Multi-Attribute Method” for measuring purity of biopharmaceuticals and improving overall control strategy. AAPS J. 2017;20:7. doi:10.1208/s12248-017-0168-3.
  • Zhang S, Bartkowiak L, Nabiswa B, Mishra P, Fann J, Ouellette D, Correia I, Regier D, Liu J. Identifying low-level sequence variants via next generation sequencing to aid stable CHO cell line screening. Biotechnol Prog. 2015;31:1077–1085. doi:10.1002/btpr.2119.
  • Chevreux G, Tilly N, Bihoreau N. Fast analysis of recombinant monoclonal antibodies using IdeS proteolytic digestion and electrospray mass spectrometry. Anal Biochem. 2011;415:212–214. doi:10.1016/j.ab.2011.04.030.
  • Ni J, Gao M, James A, Yao J, Yuan T, Carpick B, D’Amore T, Farrell P. Investigation into the misincorporation of norleucine into a recombinant protein vaccine candidate. J Ind Microbiol Biotechnol. 2015;42:971–975. doi:10.1007/s10295-015-1613-x.
  • Wen D, Vecchi MM, Gu S, Su L, Dolnikova J, Huang YM, Foley SF, Garber E, Pederson N, Meier W. Discovery and investigation of misincorporation of serine at asparagine positions in recombinant proteins expressed in Chinese hamster ovary cells. J Biol Chem. 2009;284:32686–32694. doi:10.1074/jbc.M109.059360.
  • Yu XC, Borisov OV, Alvarez M, Michels DA, Wang YJ, Ling V. Identification of codon-specific serine to asparagine mistranslation in recombinant monoclonal antibodies by high-resolution mass spectrometry. Anal Chem. 2009;81:9282–9290. doi:10.1021/ac901541h.